WHWK
$3.95
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Recent News
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Whitehawk Therapeutics CEO Dave Lennon outlined the company’s strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believe
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
Tempus AI (TEM) Soars 15% on $1.1-Billion Deal
We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]
Hedge funds investors own a significant stake of 37% in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK)
Key Insights Given the large stake in the stock by institutions, Whitehawk Therapeutics' stock price might be...